BMRN - Impact on BioMarin's Sentiment: Voxzogo's Triumph Clouded by Uncertainty | Benzinga
Raymond James initiated coverage on BioMarin Pharmaceuticals Inc (NASDAQ: BMRN) with a Market Perform rating, noting sparsity in near-term growth drivers.
Analysts Danielle Brill and Alex Nackenof say the launch of Roctavian and Voxzogo are the company's key growth drivers.
While Voxzogo's growth is expected to continue over the next few years, they worry about its longer outlook given competitive treatment options that are advancing in the clinic, including BridgeBio Pharma Inc (NASDAQ: BBIO), Ascendis Pharma A/S (NASDAQ: ASND).
The analyst also expects a slow ramp for Roctavian, given
the hemophilia doc ...